Edition:
United Kingdom

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

129.42USD
15 Feb 2019
Change (% chg)

$3.49 (+2.77%)
Prev Close
$125.93
Open
$127.19
Day's High
$129.46
Day's Low
$126.19
Volume
593,648
Avg. Vol
639,239
52-wk High
$140.76
52-wk Low
$92.57

Select another date:

Fri, Dec 21 2018

Alexion wins early U.S. approval for rare blood disorder drug

The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, an early backing that also solidifies the company's dominant market position.

UPDATE 2-Alexion wins early U.S. approval for rare blood disorder drug

Dec 21 The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, an early backing that also solidifies the company's dominant market position.

U.S. FDA approves Alexion Pharma's blood disorder drug

Dec 21 The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc's blood disorder drug Ultomiris, the pharma regulator's website showed https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108 on Friday.

Alexion to buy biotech firm Syntimmune for up to $1.2 billion

Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, bolstering its portfolio of drugs to treat rare disorders.

UPDATE 1-Alexion to buy biotech firm Syntimmune for up to $1.2 bln

Sept 26 Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, bolstering its portfolio of drugs to treat rare disorders.

Alexion to buy biotech firm Syntimmune for up to $1.2 bln

Sept 26 Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, giving it access to a rare blood disorder drug.

Select another date: